BRC team praises former FDA commissioner’s call for increased cannabis research

Former Food and Drug Administration (FDA) Commissioner Scott Gottlieb has called for increased research into cannabis-derived treatments. Yesterday, the Senate Appropriations Committee issued a report in which it called on regulators to lower the regulatory burden on cannabis research.

George Hodgin, former Navy SEAL and founder and CEO of Biopharmaceutical Research Company (BRC), issued the following statement praising the former Commissioner’s remarks and the Committee report:

“I am heartened to know that former FDA Commissioner Scott Gottlieb stands behind efforts to increase access to federally legal cannabis research. The BRC team thanks him for recognizing that the current government monopoly that has existed for over 60 years surrounding this research is insufficient to determine the medicinal promise of cannabis. He is correct that the body of evidence regarding cannabis is thin, and it will continue to be unless decisive action is taken to increase the study of these compounds.” Read more →